TY - JOUR
T1 - Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer
AU - Tsujikawa, Takahiro
AU - Crocenzi, Todd
AU - Durham, Jennifer N.
AU - Sugar, Elizabeth A.
AU - Wu, Annie A.
AU - Onners, Beth
AU - Nauroth, Julie M.
AU - Anders, Robert A.
AU - Fertig, Elana J.
AU - Laheru, Daniel A.
AU - Reiss, Kim
AU - Vonderheide, Robert H.
AU - Ko, Andrew H.
AU - Tempero, Margaret A.
AU - Fisher, George A.
AU - Considine, Michael
AU - Danilova, Ludmila
AU - Brockstedt, Dirk G.
AU - Coussens, Lisa M.
AU - Jaffee, Elizabeth M.
AU - Le, Dung T.
N1 - Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2020/7/15
Y1 - 2020/7/15
N2 - Purpose: Two studies in previously treated metastatic pancreatic cancer have been completed combining GVAX pancreas vaccine (GM-CSF–secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes–expressing mesothelin). In the current study, we compared Cy/GVAX followed by CRS-207 with (Arm A) or without nivolumab (Arm B). Patients and Methods: Patients with pancreatic adenocarcinoma who received one prior therapy for metastatic disease and RECIST measurable disease were randomized 1:1 to receive treatment on Arm A or Arm B. The primary objective was to compare overall survival (OS) between the arms. Additional objectives included assessment of progression-free survival, safety, tumor responses, CA19-9 responses, and immunologic correlates. Results: Ninety-three patients were treated (Arm A, 51; Arm B, 42). The median OS in Arms A and B were 5.9 [95% confidence interval (CI), 4.7–8.6] and 6.1 (95% CI, 3.5–7.0) months, respectively, with an HR of 0.86 (95% CI, 0.55–1.34). Objective responses were seen in 3 patients using immune-related response criteria (4%, 2/51, Arm A; 2%, 1/42, Arm B). The grade ≥3 related adverse event rate, whereas higher in Arm A (35.3% vs. 11.9%) was manageable. Changes in the microenvironment, including increase in CD8þ T cells and a decrease in CD68þ myeloid cells, were observed in long-term survivors in Arm A only. Conclusions: Although the study did not meet its primary endpoint of improvement in OS of Arm A over Arm B, the OS was comparable with standard therapy. Objective responses and immunologic changes in the tumor microenvironment were evident.
AB - Purpose: Two studies in previously treated metastatic pancreatic cancer have been completed combining GVAX pancreas vaccine (GM-CSF–secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes–expressing mesothelin). In the current study, we compared Cy/GVAX followed by CRS-207 with (Arm A) or without nivolumab (Arm B). Patients and Methods: Patients with pancreatic adenocarcinoma who received one prior therapy for metastatic disease and RECIST measurable disease were randomized 1:1 to receive treatment on Arm A or Arm B. The primary objective was to compare overall survival (OS) between the arms. Additional objectives included assessment of progression-free survival, safety, tumor responses, CA19-9 responses, and immunologic correlates. Results: Ninety-three patients were treated (Arm A, 51; Arm B, 42). The median OS in Arms A and B were 5.9 [95% confidence interval (CI), 4.7–8.6] and 6.1 (95% CI, 3.5–7.0) months, respectively, with an HR of 0.86 (95% CI, 0.55–1.34). Objective responses were seen in 3 patients using immune-related response criteria (4%, 2/51, Arm A; 2%, 1/42, Arm B). The grade ≥3 related adverse event rate, whereas higher in Arm A (35.3% vs. 11.9%) was manageable. Changes in the microenvironment, including increase in CD8þ T cells and a decrease in CD68þ myeloid cells, were observed in long-term survivors in Arm A only. Conclusions: Although the study did not meet its primary endpoint of improvement in OS of Arm A over Arm B, the OS was comparable with standard therapy. Objective responses and immunologic changes in the tumor microenvironment were evident.
UR - http://www.scopus.com/inward/record.url?scp=85086445264&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086445264&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-3978
DO - 10.1158/1078-0432.CCR-19-3978
M3 - Article
C2 - 32273276
AN - SCOPUS:85086445264
SN - 1078-0432
VL - 26
SP - 3578
EP - 3588
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 14
ER -